Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR

Abbott (ABT) and Flatiron Health announced the integration of Abbott’s comprehensive Precision Oncology portfolio into OncoEMR, Flatiron’s cloud-based Electronic Medical Record platform. Through this integration, oncology providers can now digitally order Abbott tests – individually or in combination – and receive status updates and results directly within their existing OncoEMR clinical workflow. Available Abbott tests include the Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard tests, enabling clinicians to access the comprehensive portfolio through a single, unified experience. This approach supports more informed treatment decisions across multiple stages of cancer care while helping reduce administrative burden and keeping the focus on patient care. The integration expands access to Abbott’s Precision Oncology tests across Flatiron’s national network of more than 1,600 community cancer care centers, where 4,700 providers deliver care and where most cancer care in the U.S. takes place.